

Yukihisa Fujinaga

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8331207/yukihisa-fujinaga-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

141
citations

7
h-index

9
g-index

41
ext. papers

254
ext. citations

4.1
avg, IF

2.34
L-index

#	Paper	IF	Citations
31	Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. <i>Hepatology Research</i> , 2019 , 49, 284-295	5.1	15
30	Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. <i>Antibiotics</i> , 2020 , 9,	4.9	13
29	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. <i>Microorganisms</i> , 2020 , 8,	4.9	10
28	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. <i>Hepatology Communications</i> , 2017 , 1, 928-945	6	8
27	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
26	Identification of clinical risk factors for histological progression of primary biliary cholangitis. <i>Hepatology Research</i> , 2019 , 49, 1015-1025	5.1	7
25	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
24	Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor. <i>Clinical Endoscopy</i> , 2021 , 54, 371-378	2.5	7
23	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <i>Cells</i> , 2019 , 8,	7.9	6
22	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. <i>Nutrients</i> , 2020 , 12,	6.7	6
21	Glycogenic Hepatopathy in Type 1 Diabetes Mellitus. <i>Internal Medicine</i> , 2018 , 57, 1087-1092	1.1	6
20	Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
19	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
18	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , 2019 , 49, 1147-1161	5.1	4
17	Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. <i>Hepatology Research</i> , 2019 , 49, 232-238	5.1	4
16	Effect of furosemide on muscle cramps in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 76-81	4	4
15	Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , 2018 , 16, 2743-2750	2.1	4

14	Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study. <i>Hepatology Research</i> , 2020 , 50, 1101-1105	5.1	3
13	Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020 , 26, 7232-7241	5.6	3
12	Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia. <i>Digestive Diseases</i> , 2020 , 38, 329-334	3.2	3
11	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
10	Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
9	The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. <i>Hepatology Research</i> , 2021 , 51, 31-38	5.1	2
8	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. <i>Medicine (United States)</i> , 2021 , 100, e27212	1.8	2
7	Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. <i>World Journal of Gastrointestinal Oncology</i> , 2019 , 11, 887-897	3.4	1
6	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.. <i>Indian Journal of Gastroenterology</i> , 2022 , 41, 169	1.9	1
5	Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis. <i>Medicine (United States)</i> , 2021 , 100, e27403	1.8	0
4	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2020 , 21, 1-1	2.1	
3	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2021 , 21, 30	2.1	
2	Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis. <i>BMC Gastroenterology</i> , 2021 , 21, 369	3	
1	Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.. <i>In Vivo</i> , 2022 , 36, 1477-1484	2.3	